| Autor: |
BenMarzouk-Hidalgo OJ; Unit of Infectious Diseases, Microbiology and Preventive Medicine/Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío/CSIC/University of Sevilla, Seville, Spain., Cordero E, Gómez-Cía T, Sánchez M, González-Padilla JD, Infante-Cossio P, Sicilia-Castro D, Hernández-Guisado JM, Pérez-Romero P |
| Jazyk: |
angličtina |
| Zdroj: |
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2011 Dec; Vol. 55 (12), pp. 5949-51. Date of Electronic Publication: 2011 Oct 03. |
| DOI: |
10.1128/AAC.05335-11 |
| Abstrakt: |
Little is known about cytomegalovirus (CMV) infection after face transplantation, since only two of the 11 cases of face transplantation reported worldwide have documented a CMV infection after transplantation. Herein, we present the first report of a composite-tissue face allotransplant recipient at high risk for CMV infection (D(+)/R(-) [CMV serpositive donor positive/CMV seronegative receptor]) undergoing preemptive treatment. Preemptive treatment was safe and effective for controlling CMV infection and thus promoting early acquisition of a CMV-specific immune response that protected the patient from late-onset CMV disease. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
